Entering text into the input field will update the search result below

Prevail Therapeutics rockets 85% on being acquired by Lilly for ~$1.04B

  • Eli Lilly (NYSE:LLY) inks agreement to acquire Prevail Therapeutics (NASDAQ:PRVL) for $22.50/share in cash (or an aggregate of ~$880M) payable at closing plus one non-tradable contingent value right (CVR) worth up to $4.00/share in cash (~$160M), for a total consideration of up to $26.50/share in cash, for ~$1.04B.

Recommended For You

Related Stocks

SymbolLast Price% Chg
LLY
--
PRVL
--